source
- Daraxonrasib shows 35% response rate in second‑line RAS‑mutated pancreatic cancerPhase 1/2 data from a monotherapy study of daraxonrasib in patients with RAS G12‑mutated pancreatic ductal adenocarcinoma reported an objective response rate of 35% when used as a second‑line treat…
- Astellas reports promising early results for stem cell eye therapy ASP7317 in age-related diseaseAstellas announced data from an early-stage trial of ASP7317, a stem cell-derived therapy aimed at an age-related eye condition. The study showed encouraging signs of efficacy and safety in most p…Endpoints · 4mo agoPositive readoutPositive